Ritalin LA 20 mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Attention Deficit/Hyperactivity Disorder

Drug Information

Target Indication

Attention Deficit/Hyperactivity Disorder

Clinical Trial

Last updated: 2/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Influenza

Heart Transplantation

Non-alcoholic Fatty Liver Disease (NAFLD)

Meningococcal Meningitis

Axial Spondyloarthritis